Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to -$14.9 million.

  • Orchestra BioMed Holdings' Free Cash Flow fell 7.93% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 26.19%. This contributed to the annual value of -$50.8 million for FY2024, which is 10.05% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Free Cash Flow stood at -$14.9 million for Q3 2025, which was up 4.50% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Free Cash Flow registered a high of -$5.4 million during Q1 2022, and its lowest value of -$16.7 million during Q1 2025.
  • Its 3-year average for Free Cash Flow is -$13.1 million, with a median of -$13.6 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 168.40% in 2023, then climbed by 8.29% in 2024.
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Free Cash Flow stood at -$8.8 million in 2022, then decreased by 24.70% to -$11.0 million in 2023, then dropped by 24.36% to -$13.6 million in 2024, then decreased by 7.93% to -$14.9 million in 2025.
  • Its Free Cash Flow stands at -$14.9 million for Q3 2025, versus -$15.6 million for Q2 2025 and -$16.7 million for Q1 2025.